The Forces of Magnificence® Report from The DREAM Initiative® Reveals Demand for New Requirements of Magnificence and Imagery

The Forces of Magnificence® Report from The DREAM Initiative® Reveals Demand for New Requirements of Magnificence and Imagery

Approval triggers $30.0 million milestone fee, to be acknowledged as income within the 3 rd quarter Aurinia Prescribed drugs Inc. (NASDAQ:AUPH) (Aurinia or the Firm), a biopharmaceutical firm dedicated to delivering therapeutics that change the trajectory of autoimmune illness, introduced that the European Fee (EC) has granted advertising and marketing authorization of LUPKYNIS® (voclosporin) to … Read more

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.